Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# 3T Biosciences

TCR Target ID And Therapeutic Discovery

## Sitemaps

- [XML Sitemap](https://3tbiosciences.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations](https://3tbiosciences.com/3t-biosciences-appoints-rebeca-villarreal-barragan-mba-as-head-of-clinical-operations/) - Villarreal-Barragan brings global experience delivering first-in-human and complex biomarker-driven oncology trials for Gilead Sciences, Kite Pharma, and emerging biotech companies SOUTH SAN FRANCISCO, Calif., – March 2, 2026 – 3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Rebeca Villarreal-Barragan, MBA, as
- [3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors](https://3tbiosciences.com/3t-biosciences-announces-appointments-of-behzad-kharabi-m-d-as-chief-medical-officer-and-parker-institute-for-cancer-immunotherapy-pici-ceo-karen-knudsen-mba-ph-d-to-board-of-directors/) - Kharabi led development of CD19 CAR-T therapy TECARTUS®; brings extensive cell and gene therapy expertise to guide 3T’s bispecific T-cell engager programs into the clinic Knudsen oversees more than 100 immunotherapy studies at PICI; adds deep translational oncology insight to help shape 3T’s scientific and clinical strategy SOUTH SAN FRANCISCO, Calif., January 6, 2026 —
- [3T Biosciences Strengthens Leadership Team with Promotion of Marvin Gee, Ph.D., to Chief Research Officer and Appointment of Barbara Sennino, Ph.D., as Senior Vice President and Head of Early Development](https://3tbiosciences.com/3t-biosciences-strengthens-leadership-team-with-promotion-of-marvin-gee-ph-d-to-chief-research-officer-and-appointment-of-barbara-sennino-ph-d-as-senior-vice-president-and-head-of-early-developm/) - SOUTH SAN FRANCISCO, Calif., March 4, 2025 – 3T Biosciences (“3T”), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the promotion of Marvin Gee, Ph.D., to chief research officer and the appointment of Barbara Sennino, Ph.D., as senior vice president and head of early development. These
- [3T Biosciences Builds Transatlantic Pan-Cancer Research Pipeline to Target Most Difficult-to-Treat Cancers](https://3tbiosciences.com/3t-biosciences-builds-transatlantic-pan-cancer-research-pipeline-to-target-most-difficult-to-treat-cancers/) - Collaborations with decorated academic investigators at Oxford University, VIB, KU Leuven, and University of California, San Francisco
- [Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies](https://3tbiosciences.com/boehringer-ingelheim-and-3t-biosciences-enter-into-a-second-partnership-to-develop-next-generation-cancer-immunotherapies/) - Ingelheim, Germany and South San Francisco, Calif., USA — 4 January 2023 — Boehringer Ingelheim and 3T Biosciences (“3T”) today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies. Despite the significant transformation of the cancer treatment landscape by immunotherapies, sustained remission only
- [Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies](https://3tbiosciences.com/boehringer-ingelheim-and-3t-biosciences-join-forces-to-develop-next-generation-cancer-immunotherapies/) - INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., USA, 9 January 2023 – Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and
- [3T Biosciences Announces Appointment of John Leonard, M.D. to its Board of Directors](https://3tbiosciences.com/3t-biosciences-announces-appointment-of-john-leonard-m-d-to-its-board-of-directors/) - Current president and CEO of Intellia Therapeutics and previous global head of Abbvie's R&D brings more than 30 years' experience leading discovery, development, and launch of groundbreaking blockbuster medicines SAN FRANCISCO, Calif., Oct. 25, 2022 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today
- [3T Biosciences Debuts with $40 Million Series A Financing](https://3tbiosciences.com/3t-biosciences-debuts-with-40-million-series-a-financing/) - Immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations Company secured exclusive license with Stanford University for novel TCR-mimetic discovery platform and development stage MAGE-A3 TCRs Stefan Scherer, M.D., Ph.D., named president and CEO, and Christopher DeRespino, MBA, appointed chief business officer Sean Harper,

## Pages

- [Home](https://3tbiosciences.com/) - We are solving a major bottleneck in the field of targeted biotherapeutics in oncology – the identification of novel targets for the treatment of solid tumors.
- [Careers](https://3tbiosciences.com/careers/) - 3T Biosciences' team is growing and we’re looking for enthusiastic and self-motivated individuals to bring their talents to a fast-paced environment.
- [Scientist / Sr Scientist - Therapeutic Discovery (Protein Engineering)](https://3tbiosciences.com/careers/scientist-sr-scientist-therapeutic-discovery-protein-engineering/) - Scientist / Sr Scientist – Therapeutic Discovery (Protein Engineering) 3T Biosciences is solving a major bottleneck in the field of immunotherapy – identifying novel targets that can be used to generate therapies to treat cancer in broad patient populations. We are developing transformative T cell receptor therapies for cancer and other immune-related diseases. Our proprietary
- [Team](https://3tbiosciences.com/team/) - Tact, Transparency, and Trust are the three pillars of 3T Biosciences culture. These three pillars are key to our strong focus on empowering each 3T colleague to focus on building the strength of our team and working harmoniously together.
- [Karen Knudsen, MBA, PhD](https://3tbiosciences.com/team/karen-knudsen/) - Karen Knudsen, MBA, PhD CEO, Parker Institute for Cancer Immunotherapy (PICI) Dr. Knudsen is the chief executive officer of the Parker Institute for Cancer Immunotherapy (PICI), where she leads efforts to advance bold science, catalyze cross-institutional collaboration, and accelerate breakthrough immune-based therapies with the goal of turning all cancers into curable diseases. A globally recognized
- [Behzad Kharabi, MD](https://3tbiosciences.com/team/behzad-kharabi/) - Behzad Kharabi, MD Chief Medical Officer Dr. Kharabi brings more than 20 years of academic, clinical, and global drug development experience to 3T, including various roles with increasing responsibility at Janssen Pharmaceuticals, Kite Pharmaceuticals/Gilead Sciences, and T-Knife Therapeutics. He led the clinical development for TECARTUS® (brexucabtagene autoleucel), a CD19-directed CAR-T cell therapy used to treat
- [Sr Scientist - Immunology](https://3tbiosciences.com/careers/sr-scientist-immunology/) - Sr Scientist – Immunology 3T Biosciences is solving a major bottleneck in the field of immunotherapy – identifying novel targets that can be used to generate therapies to treat cancer in broad patient populations. We are developing transformative T cell receptor directed bispecific T cell engagers for cancer and other immune-related diseases. Our proprietary experimental
- [Publications](https://3tbiosciences.com/publications/) - Publications EXPLORE PUBLICATIONS RELATED TO 3T BIOSCIENCES 3T Platform & TCR ProfilingAutoimmune DiseaseOncology IndicationsInfectious Disease Tuning T cell receptor sensitivity through catch bond engineering Science Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy Nature Biotechnology Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes Cell Facile method for screening clinical T cell receptors
- [News](https://3tbiosciences.com/news/) - View 3T Biosciences’ collection of scientific publications.
- [Eric Kaufman](https://3tbiosciences.com/team/eric-kaufman/) - Eric Kaufman Vice President, Westlake BioPartners (Board Observer) Eric Kaufman is Vice President at Westlake BioPartners, working across the portfolio and contributing to strategic firm initiatives. Previously, he was an Associate at Cantor Fitzgerald in Equity Capital Markets and an Investment Banking Analyst at Leerink Partners. During his tenure in investment banking, Mr. Kaufman worked
- [Marvin Gee, PhD](https://3tbiosciences.com/team/marvin-gee/) - Marvin Gee, PhD - Co-Founder, VP, Head of Target Discovery
- [Barbara Sennino, PhD](https://3tbiosciences.com/team/barbara-sennino/) - Barbara Sennino, PhD Senior Vice President, Head of Early Development Dr. Sennino is a seasoned expert in cancer immunotherapy, bringing over 15 years of experience from both academic institutions and biotechnology companies. Before joining 3T, she served as Vice President of Immunotherapy at Turnstone Biologics, leading the preclinical development of targeted tumor-infiltrating lymphocyte (TIL) programs.
- [Desmond Padhi, PharmD](https://3tbiosciences.com/team/desmond-padhi/) - Desmond Padhi, PharmD Operating Partner, Westlake BioPartners Dr. Padhi is an Operating Partner at Westlake BioPartners working broadly with the firm and portfolio companies to conceive, discover, and advance medicines into the clinic in all therapeutic areas and modalities. In this role he has served as founding CEO of Capsida Biotherapeutics and as interim CEO
- [Jonathan MacQuitty, PhD](https://3tbiosciences.com/team/jonathan-macquitty/) - Shelley Chu, MD, PhD - Partner, Lightspeed Venture Partners
- [Contact](https://3tbiosciences.com/contact/) - Contact us at info@3tbiosciences.com, or get in touch with us via the webform below.
- [Leah Sibener, PhD](https://3tbiosciences.com/team/leah-sibener/) - Leah Sibener, PhD - Co-Founder, VP, Head of Therapeutic Discovery
- [About](https://3tbiosciences.com/about/) - 3T's proprietary screening platform and computational technology allows us to identify prevalent T cell receptor (TCR) targets and advance effective therapies.
- [Science](https://3tbiosciences.com/science/) - 3T’s technology consists of an end-to-end target and therapeutic discovery pipeline – enabling the development of next generation therapies for solid tumors.
- [Privacy Policy](https://3tbiosciences.com/privacy-policy/) - We value your privacy very highly. Please read this Privacy Policy carefully before using the 3tbiosciences.com Website (the “Website”) operated by 3T Biosciences, a(n) Corporation formed in California, United States (“us,” “we,” “our”) as this Privacy Policy contains important information regarding your privacy and how we may use the information we collect about you.
- [Disclaimer](https://3tbiosciences.com/disclaimer/) - Disclaimer Last updated: 2020-09-15 16:01:21 Please read this Disclaimer carefully before using the 3tbiosciences.com Website (the “Website”) operated by 3T Biosciences, a(n) Corporation formed in California (“us,” “we,” “our”) as this Disclaimer contains important information regarding limitations of our liability. Your access to and use of the Website is conditional upon your acceptance of and
- [Podcast](https://3tbiosciences.com/podcast/) - In a special Heroes of ScienceTM podcast, Stefan Scherer, Leah Sibener and Marvin Gee share the story of 3T Biosciences. In this brief interview, they detail our unique history, explain our novel approach to immunotherapy, and talk about why our colleagues are so driven to bring new therapies to patients who suffer from cancer and other immunologic diseases.
- [Partnering](https://3tbiosciences.com/partnering/) - At 3T, we believe collaborations with other innovators in industry and academia are fundamental to accelerating meaningful innovation.
- [David Piacquad, MBA](https://3tbiosciences.com/team/david-piacquad/) - David Piacquad, MBA - Former SVP, Business Development at Amgen
- [Stefan Scherer, MD, PhD](https://3tbiosciences.com/team/stefan-scherer/) - Stefan Scherer, MD, PhD - Chief Executive Officer & President
- [Terms of Service](https://3tbiosciences.com/terms-of-service/) - Please read this Terms of Service (“Terms,” “Terms of Service”) carefully before using the 3tbiosciences.com Website (the “Website”) operated by 3T Biosciences, a(n) Corporation formed in California, United States (“us,” “we,” “our”) as this Terms of Service contains important information regarding limitations of our liability.
- [Stephen Schoenberger, PhD](https://3tbiosciences.com/team/stephen-schoenberger/) - Stephen Schoenberger, PhD - Professor, Developmental Immunology (La Jolla Institute for Immunology)
- [Christina Curtis, PhD, MSc](https://3tbiosciences.com/team/christina-curtis-phd-msc/) - Christina Curtis, PhD, MSc- Endowed Scholar and Associate Professor of Medicine & Genetics (Stanford)
- [Mark Davis, PhD](https://3tbiosciences.com/team/mark-davis/) - Mark Davis, PhD - The Burt and Marion Avery Family Professor, Transplantation and Infection, Microbiology & Immunology (Stanford), HHMI
- [Heinz-Josef Lenz, MD, PhD, FACP](https://3tbiosciences.com/team/heinz-josef-lenz/) - Heinz-Josef Lenz, MD, PhD, FACP- Associate Director for Clinical Research and Co-Leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center
- [K. Christopher Garcia, PhD](https://3tbiosciences.com/team/k-christopher-garcia/) - K. Christopher Garcia, PhD - Co-Founder, Chairman of the Scientific Advisory Board
- [John Connolly, PhD](https://3tbiosciences.com/team/john-connolly/) - John Connolly, PhD - Chief Scientific Officer, Parker Institute for Cancer Immunotherapy (PICI)
- [Beth Seidenberg, MD](https://3tbiosciences.com/team/beth-seidenberg/) - Beth Seidenberg, MD - Managing Director, Westlake Village BioPartners (Board Observer)
- [Christopher J DeRespino](https://3tbiosciences.com/team/christopher-j-derespino/) - Christopher J DeRespino - Chief Business Officer

## Categories

- [News](https://3tbiosciences.com/category/news/)